Megace is a progestational agent, indicated for the treatment of certain hormone dependent neoplasms, such as breast cancer.
Aims: We conducted a systematic review and meta-analysis to search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD.
This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study is designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced that the Phase III trial of roluperidone to treat negative symptoms in schizophrenia did not meet its primary (reduction in PANSS Marder Negative Symptoms Factor Score or NSFS) and key secondary (improvement in the Personal and Social Performance Scale Total Score or PSP) endpoints.
Intra-Cellular Therapies, Inc. a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Genentech/Roche announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy RG 6058 (tiragolumab) plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial (first-line) treatment for people with extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival.
Intra-Cellular Therapies, Inc. announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting
Shanghai Henlius Biotech announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) Hansizhuang (serplulimab injection), in combination with carboplatin and etoposide for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC), has been approved by the National Medical Products Administration (NMPA), making it the world's first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC)